Abstract Number: 0279 • ACR Convergence 2020
Pulmonary Involvement in a Single Center Cohort of Patients with Systemic Lupus Erythematosus
Background/Purpose: The prevalence of SLE pulmonary involvement varies depending on several factors, including diagnostic methods. In this study, we sought to determine the frequency of…Abstract Number: 0297 • ACR Convergence 2020
Towards a Glucocorticoid Exposure Signature in SLE: Effects of Type I Interferon
Background/Purpose: Glucocorticoids (GC), utilised in SLE for their broad immunosuppressive actions, predominantly mediate these effects by interaction with the cytoplasmic GC receptor (GR) to modulate…Abstract Number: 0462 • ACR Convergence 2020
Lupus-like Autoimmunity and Increased Interferon Response in Patients with STAT3-deficient Hyper-IgE Syndrome
Background/Purpose: Autosomal dominant hyper-IgE syndrome (AD-HIES), also known as Job’s syndrome, is a rare primary immunodeficiency caused by dominant-negative loss-of-function (LOF) mutations in signal transducer…Abstract Number: 0591 • ACR Convergence 2020
Intervention to Improve SLE Medication Adherence Using Surescripts Pharmacy Refill Data
Background/Purpose: Medication nonadherence is as high as 80% among SLE patients and leads to higher morbidity, mortality, and healthcare costs. Few studies have tested interventions…Abstract Number: 0846 • ACR Convergence 2020
MHC Class I Epitopes Derived from Autoantibody Variable Regions, Conjugated to Synthetic Oligodeoxynuleotides, Induce Cytotoxic T Cells That Deplete Autoreactive B Cells and Ameliorate Murine Lupus
Background/Purpose: B cell depletion or modulation is emerging as a major treatment modality for autoimmune diseases. However, the current treatments to accomplish this non-specifically target…Abstract Number: 0864 • ACR Convergence 2020
Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression in Patients with Systemic Lupus Erythematosus
Background/Purpose: Hydroxychloroquine (HCQ) has demonstrated a wide array of beneficial effects in patients with systemic lupus erythematosus (SLE), with regard to disease activity, flare rates,…Abstract Number: 0981 • ACR Convergence 2020
Mortality Among Minority Populations with Systemic Lupus Erythematosus, Including Asian and Hispanic Status: The California Lupus Surveillance Project, 2007-2017
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease with manifestations that vary widely in severity. Contemporary data indicate that minority populations are at…Abstract Number: 1024 • ACR Convergence 2020
Time Trends in the Incidence of Systemic Lupus Erythematosus: A 40-Year Study
Background/Purpose: Changes over time in the incidence of Systemic Lupus Erythematosus (SLE) remain uncertain. It is unclear if the variations in established SLE risk factors,…Abstract Number: 1262 • ACR Convergence 2020
Single LAC Positivity versus Double and Triple Positivity for Thrombosis in SLE
Background/Purpose:Antiphospholipid syndrome (APS) is classified as the development of venous and/or arterial thromboses, and pregnancy morbidity, in the presence of antiphospholipid antibodies (aPL); lupus anticoagulant,…Abstract Number: 1278 • ACR Convergence 2020
Does Co-existing Systemic Lupus Erythematosus Affect Outcomes of Hospitalizations for Ischemic Stroke?
Background/Purpose: Various studies have shown that individuals with Systemic Lupus Erythematosus (SLE) have a higher risk of stroke and cerebrovascular events than the general population. These events represent a significant…Abstract Number: 1294 • ACR Convergence 2020
Prediction of Damage in SLE Using Unbiased Analysis of Large Datasets
Background/Purpose: A key goal of treatment of SLE is the prevention of irreversible organ damage. The ability to identify patients at increased risk for damage…Abstract Number: 1475 • ACR Convergence 2020
Predictors of Thirty-Day Hospital Readmissions in Systemic Lupus Erythematosus in the US: A Nationwide Study
Background/Purpose: For individuals with systemic lupus erythematosus (SLE), hospital readmission rate is associated with quality of care and prognosis. Our objective was to evaluate independent…Abstract Number: 1616 • ACR Convergence 2020
Systematic Review of Effectiveness Outcomes Reported in Rheumatology Transition Literature
Background/Purpose: In young patients with rheumatologic disease, transition from pediatric to adult care is a complex process. Poor transitional care leads to health deterioration, loss…Abstract Number: 1679 • ACR Convergence 2020
Developing a Standardized Corticosteroid Dosing Regimen in Pediatric Proliferative Lupus Nephritis
Background/Purpose: Corticosteroids (CS) remain the mainstay of therapy for childhood-onset systemic lupus erythematosus (cSLE). However, widely accepted strategies for oral (PO) or intravenous (IV) CS…Abstract Number: 1792 • ACR Convergence 2020
Platelet-bound C4d Is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE
Background/Purpose: Platelet-bound complement activation products (PC4d), defined as PC4d20 net mean fluorescent intensity [MFI], or a thrombotic risk score that includes PC4d, C3 and anti-phosphatidylserine/prothrombin…
- « Previous Page
- 1
- …
- 125
- 126
- 127
- 128
- 129
- …
- 150
- Next Page »